# An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

> **NCT06254482** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 144 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** Votoplam

## Key facts

- **NCT ID:** NCT06254482
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-25
- **Primary completion:** 2029-07-16
- **Final completion:** 2029-07-16
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06254482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06254482, "An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06254482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*